Lilly drug slows Alzheimer's progression by 35% in trial
Reuters, 04 May 2023
An experimental Alzheimer's drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said, raising hopes for another treatment for the brain disorder that slowly destroys memory.
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en